Glycemic Variability and Its Association With Demographics and Lifestyles in a General Adult Population

Francisco Gude, MD, PhD¹, Pablo Diaz-Vidal, MPH¹, Cintia Rúa-Pérez, MPH¹,², Manuela Alonso-Sampedro, PhD¹,³, Carmen Fernández-Merino, MD, PhD⁴, Jesús Rey-García, MD⁴, Carmen Cadarso-Suárez, PhD², Marcos Pazos-Couselo, PhD⁵, José Manuel García-López, MD, PhD⁵, and Arturo Gonzalez-Quintela, MD, PhD³

Abstract

Objective: The objective was to investigate glycemic variability indices in relation to demographic factors and common environmental lifestyles in a general adult population.

Methods: The A Estrada Glycation and Inflammation Study is a cross-sectional study covering 1516 participants selected by sampling of the population aged 18 years and over. A subsample of 622 individuals participated in the Glycation project, which included continuous glucose monitoring procedures. Five glycemic variability indices were analyzed, that is, SD, MAGE, MAG, CONGA1, and MODD.

Results: Participants had a mean age of 48 years, 62% were females, and 12% had been previously diagnosed with diabetes. In the population without diabetes, index distributions were not normal but skewed to the right. Distributional regression models that adjusted for age, gender, BMI, alcohol intake, smoking status, and physical activity confirmed that all indices were positively and independently associated with fasting glucose levels and negatively with heavy drinking. SD, MAGE, and CONGA1 were positively associated with aging, and MAG was negatively associated with BMI. None of the GVI studied were influenced by physical activity. Age-group-specific reference values are given for the indices.

Conclusions: This study yielded age-specific reference values for glucose variability indices in a general adult population. Significant increases were observed with aging. Heavy drinking of more than 140 g/week was associated with significant decreases in variability indices. No differences were found between males and females. These normative ranges provide a guide for clinical care, and may offer an alternative treatment target among persons with diabetes.

Keywords
continuous glucose monitoring, glucose variability, reference values

Glycemic variability (GV) is a physiologic phenomenon which refers to fluctuations in blood glucose (BG) levels over time. It can be described as within-day variability, with differences between fasting and postprandial BG values throughout a 24-hour period, and between-day variability.

GV is emerging as a measure of glycemic control, which may be a reliable predictor of complications. Results from a systematic literature review suggest that in type 2 diabetes, glucose variability is associated with development of microvascular complications. Evidence is accumulating to indicate that high GV levels have deleterious effects beyond those of sustained chronic hyperglycemia, in terms of oxidative stress,

1Clinical Epidemiology Unit, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
2Department of Statistics and Operations Research, Universidad de Santiago, Santiago de Compostela, Spain
3Department of Internal Medicine, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
4Primary Care Center of A-Estrada, Pontevedra, Spain
5Department of Endocrinology, Hospital de Conxo, Santiago de Compostela, Spain

Corresponding Author:
Francisco Gude, MD, PhD, Clinical Epidemiology Unit, Hospital Clínico Universitario de Santiago, Travesía da Choupana, s/n, 15706 Santiago de Compostela, Spain.
Email: francisco.gude.sampedro@sergas.es
diabetes complications, cardiovascular outcomes, and mortality;\textsuperscript{2,7} though some contradictory reports also exist.\textsuperscript{8,9}

Determining the distribution of glycemic variability indices (GVI) in general populations is important for interpreting reference values. Almost all previously published data have come from patients with diabetes. Few studies into 24-hour BG profiles and glucose fluctuations have involved healthy subjects, and none have used subjects from a general population.\textsuperscript{10-13} In addition, the standard guidelines for definition and determination of reference intervals note that partitioning should be considered in cases where there are significant differences among subgroups defined by age, sex, and common exposures such as smoking or alcohol consumption.\textsuperscript{14} Since the aim of treating diabetes is to restore glycemia to that of persons without diabetes, the generation of a metric of glycemic excursions should begin with an examination of the profiles of individuals without diabetes.\textsuperscript{15} It is also crucial to define the boundary beyond which GVI take on a pathological significance.\textsuperscript{16}

Taken together, it is imperative to have valid comparative frameworks for the interpretation of individual values and population distributions of GVI. Hence, this adult population-based study investigated GVI levels in relation to demographic factors (age and sex) and common environmental lifestyles (physical activity, alcohol consumption, and smoking).

**Methods**

**Study Design**

The A Estrada Glycation and Inflammation Study (AEGIS) is a cross-sectional study which was performed in the municipality of A-Estrada, in Northwestern Spain. An age-stratified random sample of the population aged 18 years and older was drawn from Spain’s National Health System Registry.

Any subjects who could not provide written informed consent was deemed ineligible to participate in the study; this group included patients with dementia, mental retardation, cerebrovascular disease, terminal cancer, or inability to communicate.

A total of 1516 subjects agreed to participate in the study (overall participation rate, 68%), made up of 678 men (45%) and 838 women (55%). Participation was lower, not only among men (65%) versus women (71%), but also in the youngest and oldest age groups. There were no significant differences in terms of age or residence (rural/urban) between subjects who did and did not agree to participate in the study. From November 2012 through March 2015, all subjects were successively convened for 1 day at the Primary Care Center for evaluation, which comprised (1) an interviewer-administered structured questionnaire that included demographic and anthropometric data; (2) a lifestyle description, including physical exercise, alcohol consumption, and smoking; and (3) fasting venous blood sampling.

In addition, study participants were invited to participate in the glycation project, which included continuous glucose monitoring (CGM) procedures. Additional exclusion criteria in this group were inability to fulfill the protocol, eating out, allergy to adhesives, or any concomitant medical condition that would likely affect evaluation of the performance of a device. A total of 622 subjects consented to undergo a 6-day period of CGM. Study profiles are summarized in Figure 1.

**CGM Procedures**

At the start of each monitoring period, a research nurse inserted a sensor (Enlite\textsuperscript{TM}, Medtronic, Inc, Northridge, CA, USA) subcutaneously into the abdomen, and instructed the participant in the use of the CGM device (iPro\textsuperscript{TM}, Medtronic, Inc, Northridge, CA, USA). This sensor measures subcutaneous tissue interstitial glucose levels continuously, recording values every 5 min, within a range of 40-400 mg/dL (2.2-22.2 mmol/L). Participants were provided with a conventional glucometer (OneTouch\textsuperscript{®} Verio\textsuperscript{®} Pro; LifeScan, Milpitas, CA, USA) as well as compatible lancets and test strips for calibrating the CGM. Subjects were asked to make at least 3 capillary BG measurements (usually before the main meals). The capillary BG readings were performed without checking the current CGM reading, and were also used for calibration of the iPro2 CGM system. On the 7th day the sensor was removed, and the data were downloaded and stored for further analysis. In any case where the number of data-acquisition “skips” per day totaled more than 2 hours, the entire day was discarded.

Of the 622 subjects enrolled in the study, 581 completed at least 2 days of monitoring. Forty-one subjects withdrew from the study due to noncompliance with protocol demands (n = 4), or difficulties in handling the device (n = 37). Itching was reported in 60 subjects and minor redness in 11. Swelling of the skin or bruises were never seen, and none of the patients reported pain at the sensor insertion site.

**Classification of Alcohol Consumption and Smoking**

Alcohol consumption was assessed using the standard drinking unit system,\textsuperscript{17} which sums the number of glasses of wine (~10g), bottles of beer (~10g), and units of spirits (~20g). Individuals with an habitual alcohol consumption of 1-140 g/week (n = 281, 48.4%) were considered light drinkers, and those with an alcohol consumption of >140 g/week (n = 71, 12.2%) were considered heavy drinkers: the remainder (n = 229, 39.4%), made up of alcohol abstainers and very occasional alcohol drinkers, were pooled and included in the same group.

Tobacco smoking was recorded as the number of cigarettes regularly consumed per day. Consumers of at least 1 cigarette per day were considered smokers, as were individuals who had
quit smoking during the preceding year. Subjects were classified according to smoking status into the following 3 groups: (1) nonsmokers (n = 309, 53.2%), (2) ex-smokers (n = 154, 26.5%), and (3) current smokers (n = 110, 20.3%).

**Physical Activity Assessment**

Subjects completed the International Physical Activity Questionnaire (short form), from which we calculated metabolic equivalent of task and hours per week engaged in vigorous and moderate activities and walking, as described by Craig et al. We then classified them according to the 3 levels of physical activity: (1) “inactive” (n = 209, 36.0%), (2) “minimally active” (n = 223, 38.4%), and (3) “HEPA active” (health-enhancing physical activity; a high active category, n = 149, 25.6%).

**Laboratory Determinations**

The HbA1c was determined by high-performance liquid chromatography. All HbA1c values were converted to Diabetes Control and Complications Trial–aligned units. Glucose was determined in fasting serum samples by the glucose oxidase peroxidase method.

**Measures of Glycemic Variability**

After downloading the recorded data, 4 GVI were analyzed, that is, standard deviation (SD), mean amplitude of glycemic excursions (MAGE), mean absolute glucose (MAG) change per patient per hour, continuous overlapping net glycemic action at 1 h (CONGA1), and the mean of daily differences (MODD). The mathematical formulae of the methods of assessment for glucose variability were taken from their original publications for inclusion in an R program, which is available free of charge for noncommercial use (Table 1).

**Ethical Considerations**

The present study was reviewed and approved by the Clinical Research Ethics Committee from Galicia, Spain.
Table 1. Function in R to Extract Glycemic Variability Indices From csv Files.

```
# index(data, d, n)
# Arguments
# data is a database with covariates: id (identification), day (1, 2, 3, ...), Glucose (mg/dl)
# d, time (in min) between two consecutive glucose measurements
# n, for CONGAn estimation (at 1, 2, ... hours)

index <- function(data, d, n) {
  glucosemg <- data$Glucose
  day <- data$day
  id <- unique(data$id)
  glucose <- glucosemg/18
  N <- length(glucose)
  m <- length(table(day)) # number of monitoring days
  Th <- 24*m # total time in hours
  # number of observations in 1 hour
  K <- dim(data[day == 1, ])[1]
  dat <- cbind(c(1:N), data)
  colnames(dat)[1] <- "num" ; orden <- dat$num
  sd <- tapply(dat$glucose, dat$day, sd) # SD for each day
  IGV <- 120 # Ideal glucose value
  MG <- mean(glucosemg)
  SD <- sd(glucosemg)
  CV <- 100*SD/MG
  IQR <- IQR(glucosemg)
  M <- mean(abs(10*log10(glucosemg/IGV))^3) + (max(glucosemg)-min(glucosemg))/20 # M-value
  J <- 0.001*(MG + SD)^2 # J-Index (mg/dl)
  # J <- 0.324*(MG + SD)^2 # J-Index (mmol/l)
  FG <- 1.509*(log(glucosemg)^1.084 - 5.381)
  rl <- ifelse(FG < 0, 10*FG^2, 0)
  rh <- ifelse(FG > 0, 10*FG^2, 0)
  LBGI <- 1/N*sum(rl) # Low Blood Glucose Index
  HBGI <- 1/N*sum(rh) # High Blood Glucose Index
  LR = HR = NULL
  for (i in 1:m) {
    LR <- max(rl[day == i])
    HR <- max(rh[day == i])
  }
  ADRR <- 1/m*sum(LR + HR) # Average Daily Risk Ratio
  HYPO <- 100*mean(glucosemg < 70) # Hypoglycaemia (%)
  HYPER <- 100*mean(glucosemg > 140) # Hyperglycaemia (%)
  LI <- sum((glucose[1:N-1] - glucose[2:N])^2)/d # Lability Index

  GRADE <- median(425*(log10(log10(glucose)) + 0.16)^2)
  # Continuous Overall Glycemic Action
  CONGA <- sd(glucose[(n+1):N] - glucose[1:(N-n)]
  # Mean of Daily Differences
  MODD <- sum(abs(glucose[(n+1):N] - glucose[(1+K):N])) / (K*m-1)
  # Area under the curve
  AUC <- (1/2*5*sum(glucosemg[1:N-1] + glucosemg[2:N])) / (m^2*460)

  infl = maxi = mini = dif = downs = NULL
```

(continued)
for (i in 2:(N - 1)) {
    if ((glucosemg[i] - glucosemg[i - 1]) * (glucosemg[i + 1] - glucosemg[i]) <= 0) {
        infl = c(infl, i)
    }
}

infl <- c(infl, N)
eps <- 8
n_infl <- length(infl)
for (i in 1:n_infl) {
    I1 <- ((infl[i] - eps):(infl[i] + eps))
    I <- subset(I1, I1 <= max(infl) & 0 < I1)
    if (max(glucosemg[I]) == glucosemg[infl[i]] | min(glucosemg[I]) == glucosemg[infl[i]]) {
        maxi = c(maxi, infl[i])
        mini = c(mini, infl[i])
    }
}

mm <- c(sort(c(maxi, mini)), infl[n_infl])
def <- ifelse(glucosemg[mm[1:length(mm)-1]] == glucosemg[mm[2:length(mm)]]), NA, mm[1:length(mm)-1])
def <- c(subset(def, def != "NA"), infl[n_infl])
for (k in 1:m) {
    ii <- day[def] == k
def = def[ii]
diff = NULL
    for (j in 1:length(def)) {
        diff <- c(diff, glucosemg[def[j]] - glucosemg[def[j + 1]])
    }
}
downs <- c(downs, (subset(diff, diff > 0 & diff > sd(k))}
}
MAGE <- sum(downs)/length(downs)
values <- round(c(id, MG, SD, CV, IQR, M, AdM, J, LBGI, HBGI, ADRR,
    HYPO, HYPER, LI, MAG, GRADE, MAGE, CONGA, MODD, AUC), 6)
return(values)
}

Table 1. (continued)

(CEIC2012-025). Written informed consent was obtained from each participant in the study, which conformed to the current Helsinki Declaration.

Statistical Analyses

The optimal GVI cut-off points for distinguishing subjects with and without diabetes were computed using the Youden J statistic.24

Different distributions were fitted to the observed distribution of the different GVI, using Generalized Additive Models for Location Scale and Shape (GAMLSS).25 GAMLSS allow for modeling, not only the mean response µ (ie, the location), but also other distribution parameters, such as standard deviation σ (ie, the scale) or skewness and kurtosis (ie, the shape parameters), as a function of a set of explanatory variables.

Goodness of fit was assessed by the Bayesian information criterion and Q-Q plots, to select the final model including the fitted distribution of GVI and the influence of covariates on the distribution parameters. Worm plots were used as a diagnostic tool to assess whether adjustment for kurtosis and/or skewness was required.26

Percentile curves of GVI as a function of the covariate age were calculated on the basis of the GAMLSS regression models that displayed the best goodness of fit. To facilitate the clinical use of our percentile curve data, we defined cut points at the 90th, 95th, and 97.5th percentiles for GVI.

All statistical analyses were performed using the R statistical software environment (version 3.0.2; R Foundation, http://www.r-project.org) with the “gamlss” and “OptimalCutpoints” packages.

Results

Subject Characteristics

Participants had a mean age of 48 years (range 18 to 87), 62% were females and 70 (12%) had been previously diagnosed of diabetes. Among patients with diabetes, 69% took oral antidiabetics, 4% insulin alone, and 17% insulin plus
oral drugs, and 10% were not taking insulin neither oral anti-diabetics. Subjects with diabetes were older (61 ± 12 vs 46 ± 14 years; \( P < .001 \)), contained a higher proportion of men (50% vs 36%; \( P < .001 \)), and had a higher BMI (31.2 ± 5.1 vs 27.8 ± 5.1 kg/m²; \( P < .001 \)) than those without diabetes. As expected, levels of fasting glucose and HbA1c were higher among subjects with diabetes than among those without diabetes (134 ± 35 vs 88 ± 11 mg/dL and 7.1 ± 1.2 vs 5.3 ± 0.3%, respectively).

**Distribution of Glycemic Variability Indices in the Population**

Figure 2 shows nonparametric kernel density estimates of the GVI distributions in populations with and without diabetes.

GVIs were highly correlated, showing correlation coefficients that ranged from 0.74 (between MAG and MODD) to 0.96 (between SD and MAGE).

As expected, GVI were higher among subjects with diabetes than among those without diabetes. Table 2 also shows the distribution of cut-off values for all GVI, with their corresponding sensitivities, specificities and areas under the ROC curve (AUCs) for distinguishing individuals with and without diabetes. All indices had a high discriminative ability for distinguishing individuals with and without diabetes, with values ranging from 0.80 to 0.89 for AUCs.

GVIs distributions were not normal but skewed to the right (Figure 2). In the population without diabetes, the best fit in GAMLSS was obtained as follows: for SD and MAG, using the log-normal distribution with parameters \( \log(\mu) \) and \( \log(\sigma) \)
Table 3. Glycemic Variability Indices (Univariate Analysis) in Relation to Age, Sex, Body Mass Index, and Lifestyle, in the Population Without Diabetes.

| Age group (years) | n (%) | SD          | MAGE        | MAG          | CONGA1       | MODD         |
|-------------------|-------|-------------|-------------|--------------|--------------|--------------|
| 18-29             | 70    | (14)        | 14 (8, 19)  | 23 (14, 40)  | 13 (8, 20)   | 0.68 (0.42, 1.13) | 0.68 (0.42, 1.00) |
| 30-39             | 101   | (20)        | 15 (9, 23)  | 24 (17, 44)  | 13 (8, 22)   | 0.70 (0.44, 1.25) | 0.65 (0.42, 1.08) |
| 40-49             | 126   | (24)        | 14 (9, 24)  | 26 (15, 45)  | 14 (8, 22)   | 0.74 (0.48, 1.29) | 0.64 (0.39, 1.12) |
| 50-59             | 102   | (20)        | 15 (9, 23)  | 28 (17, 44)  | 14 (8, 22)   | 0.78 (0.43, 1.21) | 0.68 (0.43, 1.15) |
| 60+               | 112   | (22)        | 15 (9, 28)  | 28 (16, 49)  | 14 (9, 22)   | 0.80 (0.47, 1.44) | 0.70 (0.38, 1.20) |
| Gender            |       |             |             |              |              |              |                |
| Female            | 326   | (64)        | 15 (9, 26)  | 26 (17, 45)  | 14 (9, 22)   | 0.74 (0.46, 1.28) | 0.66 (0.42, 1.13) |
| Male              | 185   | (36)        | 15 (8, 23)  | 26 (15, 43)  | 14 (9, 22)   | 0.76 (0.44, 1.22) | 0.67 (0.38, 1.09) |
| Body mass index   |       |             |             |              |              |              |                |
| Normal weight     | 159   | (31)        | 15 (9, 23)  | 26 (16, 42)  | 14 (9, 21)   | 0.75 (0.44, 1.22) | 0.66 (0.40, 1.08) |
| Overweight        | 194   | (38)        | 15 (9, 25)  | 26 (16, 46)  | 13 (9, 22)   | 0.73 (0.44, 1.29) | 0.66 (0.41, 1.12) |
| Obese             | 158   | (31)        | 15 (9, 26)  | 26 (16, 49)  | 14 (9, 22)   | 0.76 (0.45, 1.33) | 0.68 (0.39, 1.16) |
| Alcohol intake    |       |             |             |              |              |              |                |
| Abstainers        | 198   | (39)        | 15 (9, 26)  | 27 (17, 43)  | 14 (9, 22)   | 0.74 (0.47, 1.21) | 0.67 (0.44, 1.14) |
| Light drinkers    | 254   | (50)        | 15 (9, 25)  | 26 (15, 48)  | 13 (9, 22)   | 0.74 (0.43, 1.32) | 0.68 (0.42, 1.11) |
| Heavy drinkers    | 59    | (11)        | 14 (8, 20)  | 25 (15, 40)  | 13 (8, 20)   | 0.75 (0.43, 1.03) | 0.61 (0.37, 1.05) |
| Smoking           |       |             |             |              |              |              |                |
| Nonsmokers        | 271   | (53)        | 15 (9, 26)  | 26 (16, 46)  | 14 (9, 22)   | 0.69 (0.44, 1.26) | 0.69 (0.44, 1.17) |
| Ex-smokers        | 133   | (26)        | 14 (8, 23)  | 26 (15, 45)  | 14 (8, 22)   | 0.74 (0.44, 1.32) | 0.66 (0.37, 1.03) |
| Smokers           | 107   | (21)        | 14 (9, 22)  | 25 (15, 41)  | 13 (9, 21)   | 0.72 (0.47, 1.14) | 0.65 (0.38, 1.04) |
| Physical activity |       |             |             |              |              |              |                |
| Inactive          | 183   | (36)        | 15 (9, 26)  | 27 (17, 47)  | 14 (9, 22)   | 0.74 (0.46, 1.29) | 0.67 (0.45, 1.17) |
| Minimally active  | 192   | (37)        | 15 (9, 25)  | 27 (15, 47)  | 14 (9, 22)   | 0.74 (0.43, 1.23) | 0.67 (0.40, 1.11) |
| HEPA active       | 136   | (27)        | 14 (9, 23)  | 25 (15, 43)  | 14 (8, 21)   | 0.74 (0.43, 1.21) | 0.67 (0.40, 1.11) |

Data are medians and 5th-95th percentile ranges (in brackets), and P values [in square brackets]. Individuals with alcohol consumption of 1-140 g/week were considered light drinkers, and those with alcohol consumption > 140 g/week were considered heavy drinkers. Alcohol abstainers and very occasional alcohol drinkers were pooled in the same category. Normal weight, body mass index (BMI) < 25 kg/m²; overweight, BMI 25-30 kg/m²; obese, BMI > 30 kg/m². HEPA active, health enhancing physical activity, a high active category.

modeled linearly; for MAG and CONGA1, using the reverse Gumbel distribution with parameters μ and log(σ) modeled linearly; and for MODD, using the inverse Gaussian distribution with parameters log(μ) and log(σ) modeled linearly.

Relation of Glycemic Variability Measures With Age, Gender, BMI, and Lifestyle in the Population Without Diabetes

The univariate distribution of GVI in the population without diabetes according to gender, age, BMI, smoking habit, alcohol consumption, and physical activity is shown in Table 3.

In the population without diabetes, no significant differences were found between men and women in any of the GVI. However, significant age-related differences were found in the SD, MAGE, and CONGA1 indices, though not in MAG and MODD.

Drinkers of more than 140 g/week had the lowest GVI when compared with other categories of alcohol consumption. Light drinkers had similar GVI to abstainers. Ex-smokers had the lowest SD levels when compared with other categories of tobacco consumption. No significant differences were found in any of the indices in terms of BMI or physical activity.

To further elucidate the influence of variables that might be associated both with BG levels and with GVI, a multivariate analysis was performed (See Table 4). Distributional regression models adjusted for age, gender, BMI, alcohol intake, smoking status, and physical activity confirmed that all indices were positively and independently associated with fasting glucose levels and negatively with heavy drinking. SD, MAGE, and CONGA1 were positively associated with aging, and MAG was negatively associated with BMI. None of the GVI studied were influenced by physical activity. Although MAG and MODD were not associated with age, age-specific reference values are given for all the studied indices (Table 5), and percentiles are shown in Figure 3.

Discussion

This article reports age-specific reference values for glucose variability indices drawn from a general adult population.
population aged 18-90 years. According to our results, while GVI showed significant increases with aging and significant decreases in heavy drinkers of more than 140 g/week, no differences were found between males and females. These results show that age- and alcohol-related changes in GVI are independent of potential confounders, such as levels of fasting glucose, BMI, smoking, and physical activity.

As expected, GVI were also found to differ significantly between individuals with and without diabetes. In the population without diabetes, 90th percentile values for GVI were very close to the optimal cut-off points obtained by using the Youden criterion for discriminating between individuals with and without diabetes. AUCs registered values above 0.8, thus showing that GVI could be useful tools for distinguishing between subjects with and without diabetes.

Table 4. Results of the Multivariate Distributional Analysis for Glycemic Variability Indices in Relation to Age, Sex, Body Mass Index, and Lifestyle, After Adjusting for Glucose Fasting Levels, in the Population Without Diabetes.

|                | SD          | MAGE        | MAG          | CONGAI       | MODD        |
|----------------|-------------|-------------|--------------|--------------|-------------|
|                | Coeff (SE) P value | Coeff (SE) P value | Coeff (SE) P value | Coeff (SE) P value | Coeff (SE) P value |
| Intercept      | 2.203 (.117) .000 | 13.22 (2.844) .000 | 2.352 (.106) .000 | 0.398 (.097) .000 | -0.840 (.122) .000 |
| Age, years     | 0.002 (.001) .403 | 0.066 (.026) .010 | 0.001 (.001) .400 | 0.002 (.001) .003 | -0.001 (.001) .518 |
| BMI, kg/m²     | 0.001 (.003) .685 | -0.001 (.074) .990 | -0.006 (.003) .017 | -0.004 (.002) .996 | 0.004 (.003) .187 |
| Gender (1: Men)| -0.008 (.029) .779 | -0.115 (.741) .877 | 0.032 (.027) .227 | 0.010 (.021) .651 | 0.007 (.030) .819 |
| Smoking        |             |             |              |              |              |
| Nonsmoker      | Reference   | Reference   | Reference    | Reference    | Reference    |
| Ex-smoker      | -0.058 (.031) .661 | -0.721 (.751) .337 | -0.017 (.028) .551 | 0.010 (.021) .943 | -0.088 (.031) .005 |
| Smoker         | -0.011 (.034) .739 | -0.076 (.836) .926 | 0.005 (.031) .878 | 0.002 (.023) .143 | -0.014 (.035) .679 |
| Alcohol consumption |         |             |              |              |              |
| Abstainer      | Reference   | Reference   | Reference    | Reference    | Reference    |
| Light drinker  | -0.031 (.430) .283 | -1.098 (.698) .116 | -0.038 (.026) .144 | -0.029 (.019) .143 | -0.002 (.029) .949 |
| Heavy drinker  | -0.151 (.047) .001 | -2.944 (1.166) .012 | -0.144 (.043) .001 | -0.081 (.033) .014 | -0.133 (.047) .005 |
| Physical activity |         |             |              |              |              |
| Inactive       | Reference   | Reference   | Reference    | Reference    | Reference    |
| Minimally active | -0.028 (.030) .399 | -0.771 (.717) .283 | -0.014 (.027) .599 | -0.022 (.020) .264 | -0.032 (.030) .287 |
| HEPA active    | -0.031 (.033) .356 | -0.737 (.804) .359 | -0.016 (.030) .605 | -0.007 (.023) .747 | -0.029 (.034) .400 |
| Glucose, mg/dL | 0.005 (.001)² 0.000 | 0.107 (.035)³ 0.003 | 0.005 (.001)² 0.000 | 0.004 (.001)² 0.008 | 0.005 (.001)² 0.000 |
| Sigma intercept (log) | -1.252 (.031) .000 | 1.921 (.035) .000 | -1.349 (.031) .000 | -1.658 (.054) .000 | -1.248 (.049) .000 |
| Mu link        | Log         | Identity    | Log          | Identity    | Log          |
| Distribution type | Log normal | Reverse Gumbel | Log normal   | Reverse Gumbel | Inverse Gaussian |

²Splines used for parameter estimation.

Table 5. Suggested Cut-Points for Glycemic Variability Indices Based on the Average Predicted Value Within Each Age Group and 90th, 95th, and 97.5th Percentiles.

| Age, years | SD | 90 | 95 | 97.5 | 90 | 95 | 97.5 | 90 | 95 | 97.5 | 90 | 95 | 97.5 | 90 | 95 | 97.5 |
|------------|----|----|----|------|----|----|------|----|----|------|----|----|------|----|----|------|
| 20         | 20 | 22 | 25 | 37   | 42 | 49 | 19   | 21 | 22 | 1.05 | 1.20 | 1.38 | 0.95 | 1.05 | 1.20 |
| 25         | 20 | 22 | 25 | 38   | 42 | 49 | 19   | 21 | 22 | 1.06 | 1.21 | 1.39 | 0.96 | 1.06 | 1.21 |
| 30         | 20 | 23 | 26 | 38   | 43 | 50 | 19   | 21 | 23 | 1.08 | 1.23 | 1.40 | 0.97 | 1.07 | 1.21 |
| 35         | 21 | 23 | 26 | 39   | 43 | 50 | 19   | 21 | 23 | 1.09 | 1.24 | 1.41 | 0.97 | 1.08 | 1.22 |
| 40         | 21 | 23 | 27 | 39   | 44 | 51 | 19   | 21 | 23 | 1.10 | 1.25 | 1.42 | 0.98 | 1.09 | 1.23 |
| 45         | 21 | 23 | 27 | 40   | 44 | 51 | 19   | 21 | 23 | 1.11 | 1.26 | 1.44 | 0.99 | 1.10 | 1.24 |
| 50         | 22 | 24 | 27 | 40   | 45 | 52 | 19   | 21 | 23 | 1.12 | 1.27 | 1.45 | 0.99 | 1.11 | 1.25 |
| 55         | 22 | 24 | 28 | 40   | 45 | 52 | 19   | 21 | 23 | 1.14 | 1.29 | 1.46 | 1.00 | 1.11 | 1.26 |
| 60         | 23 | 25 | 28 | 41   | 46 | 53 | 20   | 22 | 24 | 1.15 | 1.30 | 1.47 | 1.01 | 1.12 | 1.27 |
| 65         | 23 | 25 | 29 | 41   | 46 | 53 | 20   | 22 | 24 | 1.16 | 1.31 | 1.49 | 1.01 | 1.13 | 1.28 |
| 70         | 23 | 26 | 29 | 42   | 47 | 53 | 20   | 22 | 24 | 1.17 | 1.32 | 1.50 | 1.02 | 1.14 | 1.29 |
| 75         | 24 | 26 | 30 | 42   | 47 | 54 | 20   | 22 | 24 | 1.19 | 1.33 | 1.51 | 1.03 | 1.15 | 1.30 |
| 80         | 24 | 26 | 31 | 43   | 48 | 54 | 20   | 22 | 24 | 1.20 | 1.35 | 1.52 | 1.04 | 1.16 | 1.31 |
Most studies investigating reference values for glucose variability have been conducted on patients with diabetes, with few having addressed healthy subjects, and none—at least to our knowledge—having addressed a representative sample of the general population. In the largest study published to date, which involved 434 healthy volunteers, Zhou et al. found that SD and MAGE were non-normally distributed within the population and tended to increase with age, and that neither SD nor MAGE showed a significant difference between men and women. Median values for both parameters were 0.75 mmol/L (14 mg/dL) and 1.73 mmol/L (31 mg/dL), similar to those obtained by us (SD 15 mg/dL, MAGE 26 mg/dL) and by the study conducted by the Juvenile Diabetes Research Foundation on 74 healthy individuals without diabetes (SD 14 mg/dL, MAGE 28 mg/dL). In the latter, however, measures of glucose variability were not influenced by age. Similar results were also reported by Hill et al. for MAGE but not for SD, in a study undertaken on adult subjects without diabetes in different ethnic groups. Unlike Zhou et al., who recommend a unified cut-off point for the normal reference values of the CGM parameters without differentiation by age or sex, our study indicates cut-off points that vary with aging.

Different indices have been proposed for assessing GV, and no consensus has yet been reached as regards which are clinically most useful. An US expert panel of diabetes specialists met in 2012 to discuss recommendations for standardization of analysis and presentation of glucose monitoring data. The majority (69%) of panel members indicated that SD was the most widely used and understood metric for assessing and reporting GV. In addition to SD, MAGE is a popular metric to quantify glucose variability. MAGE has been criticized on a number of grounds: (1) the qualifying limit of 1 SD is arbitrary; (2) its calculation is operator-dependent when a graphical approach is used; and (3) only the ascending or descending limb is used for its calculation. Another criticism of MAGE found is its high correlation with SD, in this study 0.96. To exclude operator-dependent influences, we developed a computer software program for calculating MAGE values, based on the criterion that descending glucose excursions exceed 1 SD of the arithmetic mean of 24-hour periods. However, in a study evaluating software programs for the calculation of MAGE, Sechterberger et al. found varying agreement among 4 available programs when applied to the same set of continuous glucose monitoring (CGM) traces, which would add other limitation to the previously reported. CONGA was the first GV metric to be specifically designed for CGM data. As CONGA does not require arbitrarily defined glucose cut-offs or changes in glucose levels, this approach provides a more objective assessment of GV over short time intervals. The absolute mean of daily differences (MODD) was developed to evaluate interday variability; this approach calculates the mean absolute value of the differences between glucose values on 2 consecutive days at the same time. However, the timing of meals can greatly affect MODD scores, making a strict dietary regimen essential for accurate monitoring.
As in the case of populations with diabetes, GVI are not symmetrically distributed: the larger values are further away from the mean than the smaller values, which means that the normal distribution might not be appropriate to fit GV data. Percentile curves were calculated using the so-called GAMLSS, developed by Rigby and Stasinopoulos. This method is an extension of the least mean squares method for modeling age-dependent GVI distribution, while accounting for the dispersion, kurtosis and, in particular, skewness of this distribution.

An interesting finding of our study is that, in free living conditions, consumers without diabetes of more than 140 g of alcohol per week showed lower GVI than did abstainers without diabetes and light drinkers. Alcohol consumption is a recognized risk factor for hypoglycemia in individuals with type 1 diabetes, and a recent meta-analysis showed that moderate alcohol consumption decreased fasting insulin concentrations among subjects without diabetes.

Physical activity is widely recognized as an important component of a healthy lifestyle. In the present study, physical activity showed no association with any GVI. In a clinical trial on patients with type 1 diabetes, Kapitza et al found no differences in the glucose profiles with respect to the exercise challenge and some studies have shown that subjects with normal glucose tolerance do not improve insulin sensitivity, glucose regulation, or insulin release in response to exercise interventions.

Our study has several limitations. First, the fact that these curves were derived from a cross-sectional study means that they provide accurate GV values in a European population but no information about the evolution of GV over time. Second, at the present time, the reference value database does not contain outcome data. Whether the reference values should be used as cut-off values for treatment remains to be discussed. Prospective studies and clinical trials are needed to determine whether percentile-based GVI have a role in identifying patients at higher risk of developing cardiovascular complications. Taken together with the long time span of recruitment, this could increase the scattering of the reference values provided; on the other hand, however, it also improves the external validity of our results.

Conclusions

These age-specific reference values for GVI may well serve as an orientation of glucose variability values in adult populations without diabetes in the context of standard medical practice.

Abbreviations

AEGIS, A Estrada Glycation and Inflammation Study; BG, blood glucose; BMI, body mass index; CGM, continuous glucose monitoring; CONGA1, continuous overlapping net glycemic action at 1 h; GAMLSS, Generalized Additive Models for Location Scale and Shape; GV, Glycemic variability; GVI, glycemic variability indices; HbA1c, hemoglobin A1c; HEPA, health-enhancing physical activity; MAG, mean absolute glucose change; MAGE, mean amplitude of glycemic excursions; MODD, the mean of daily differences; SD, standard deviation.

Acknowledgments

The A Estrada Glycation and Inflammation Study (AEGIS) group would like to acknowledge the efforts of the participants and thank them for participating.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The content is the sole responsibility of the authors and does not necessarily represent the official views of the ISCIII or Medtronic Inc. Representatives of the latter funding agency were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. No other potential conflicts of interest relevant to this article were reported. All authors confirm that neither the manuscript nor any part of it has been published or is under consideration for publication elsewhere.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research project was supported by grants from Spain’s Carlos III Institute of Health (Instituto de Salud Carlos III/ISCIII) (PI11/02219 & PI13/02594) and the European Regional Development Fund (FEDER). PDV and MAS were supported by ISCIII Preventive Activity & Health Promotion Research Network (Red de Investigación en Actividades Preventivas y de Promoción del Salud/ redIAPP) grants RD06/0018/0006 & RD12/0005/0007, respectively. CCS has been partially supported by the Spanish Ministry of Science and Innovation (MTM2015-69068-REDT). This work was also supported by a grant from Medtronic Inc.

References

1. Smith-Palmer J, Brändle M, Trevisan R, et al. Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. *Diabetes Res Clin Pract*. 2014;105:273-284.
2. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c independent risk factor for diabetic complications. *JAMA*. 2006;295:1707-1708.
3. Muggeo M, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. *Diabetes Care*. 2000;23:45-50.
4. Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. *Diabetes*. 2008;57:1349-1354.
5. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. *JAMA*. 2006;295:1681-1687.
6. Pflueger A, Abramowitz D, Calvin AD. Role of oxidative stress in contrast-induced acute kidney injury in diabetes mellitus. Med Sci Monit. 2009;15:RA125-RA136.
7. Hermanides J, Vriesendorp TM, Bosman RJ, et al. Glucose variability is associated with intensive care mortality. Crit Care Med. 2010;38:838-842.
8. Kilpatrick ES, Rigby AS, Atkin SL. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care. 2009;32:1901-1903.
9. Siegelaar SE, Kilpatrick ES, Rigby AS, et al. Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia. 2009;52:2229-2232.
10. Zhou J, Li H, Ran X, et al. Reference values for continuous glucose monitoring in Chinese subjects. Diabetes Care. 2009;32:1188-1193.
11. Zhou J, Li H, Ran X, et al. Establishment of normal reference ranges for glycemic variability in Chinese subjects using continuous glucose monitoring. Med Sci Monit. 2011;17:CR9-CR13.
12. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Fox LA, Beck RW, Xing D. Variation of interstitial glucose measurements assessed by continuous glucose monitors in healthy, non-diabetic individuals. Diabetes Care. 2010;33:1297-1299.
13. Hill NR, Oliver NS, Choudhary P, et al. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther. 2011;13:921-928.
14. Horn PS, Pesce AJ. Reference intervals: an update. Clin Chim Acta. 2003;344:5-23.
15. Service FJ. Glucose variability. Diabetes. 2013;62:1398-1404.
16. Suh S, Kim JH. Glycemic variability: how do we measure it and why is it important? Diabetes Metab J. 2015;39:273-282.
17. Gual A, Martos AR, Lligoña A, et al. Does the concept of a standard drink apply to viticultural societies? Alcohol Alcohol. 1999;34:153-160.
18. The-IPAQ-Group International Physical Activity Questionnaire. Available at: https://sites.google.com/site/theipaq/home. Accessed January 2012.
19. Craig CL, Marshall AL, Sjostrom M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35:1381-1395.
20. Hoelzel W, Weykamp C, Jeppsson JO, et al. IFCC Working Group on HbA1c Standardization: IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem. 2004;50:166-174.
21. Service FJ, Molnar GD, Rosevear JW, et al. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970;19:644-655.
22. McDonnell CM, Donath SM, Vidmar SI, et al. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther. 2005;7:253-263.
23. Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia 1972;8:342-348.
24. Lopez-Raton M, Rodriguez-Alvarez MX, Cadarso Suarez C, et al. OptimalCutpoints: An R package for selecting optimal cutpoints in diagnostic tests. J Stat Softw. 2014;61:1-36.
25. Rigby RA, Stasinopoulos DM. Generalized additive models for location, scale and shape, (with discussion). Appl Statist. 2005;54(3):507-554.
26. van Buuren S, Fredriks M. Worm plot: a simple diagnostic device for modelling growth reference curves. Stat Med. 2001;20:1259-1277.
27. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile (AGP). J Diabetes Sci Technol. 2013;7:562-578.
28. DeVries JH. Glucose variability: where it is important and how to measure it. Diabetes. 2013;62:1405-1408.
29. Sechterberger MK, Luijf YM, Devries JH. Poor agreement of computerized calculators for mean amplitude of glycemic excursions. Diabetes Technol Ther. 2014;16:72-75.
30. Turner B, Jenkins E, Kerr D, et al. The effect of evening alcohol consumption on next-morning glucose control in type 1 diabetes. Diabetes Care. 2001;24:1888-1893.
31. Schrieks IC, Heil AL, Hendriks HF, et al. The effect of alcohol consumption on insulin sensitivity and glycemic status: a systematic review and meta-analysis of intervention studies. Diabetes Care. 2015;38:723-732.
32. Kapitza C, Hövelmann U, Nosek L, Kurth HJ, Essenpreis M, Heinemann L. Continuous glucose monitoring during exercise in patients with type 1 diabetes on continuous subcutaneous insulin infusion. J Diabetes Sci Technol. 2010;4:123-131.
33. Jenkins NT, Hagberg JM. Aerobic training effects on glucose tolerance in prediabetic and normoglycemic humans. Med Sci Sports Exerc. 2011;43:2231-2240.